{"entity":{"id":"nct02823405","kind":"trial","name":"X4P-001 and Pembrolizumab in Patients With Advanced Melanoma","aka":[],"tldr":"A phase 1 trial of Mavorixafor and Pembrolizumab in Melanoma, run by X4 Pharmaceuticals, completed.","summary":"X4P-001 and Pembrolizumab in Patients With Advanced Melanoma is a phase 1 interventional study registered as NCT02823405 by X4 Pharmaceuticals, with 16 participants recorded, started 2016-09-15 and reaching its primary completion in 2018-03-15. Interventions recorded: X4P-001, Pembrolizumab. Conditions recorded: Melanoma.\n\nLinked to the drug Mavorixafor because the registry names it among its interventions and Melanoma among its conditions. Registry record only: no result has been read by an editor.","status":"completed","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02823405","url":"https://clinicaltrials.gov/study/NCT02823405"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":["mavorixafor","pembrolizumab"],"companies":["x4-pharmaceuticals"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02823405","phase":"1","setting":"A Phase 1b Trial of X4P-001 Alone and With Pembrolizumab in Patients With Advanced Melanoma","sponsor":"X4 Pharmaceuticals","enrolled":16,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02823405/","neighbours":{"cancer":[{"id":"melanoma","kind":"cancer","name":"Melanoma","route":"/cancers/melanoma/"}],"drug":[{"id":"mavorixafor","kind":"drug","name":"Mavorixafor","route":"/drugs/mavorixafor/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"company":[{"id":"x4-pharmaceuticals","kind":"company","name":"X4 Pharmaceuticals","route":"/companies/x4-pharmaceuticals/"}]}}